A detailed history of Equitable Holdings, Inc. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Equitable Holdings, Inc. holds 210,000 shares of SLS stock, worth $247,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares
210,000
Previous 200,000 5.0%
Holding current value
$247,800
Previous $202,000 23.27%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.06 - $1.63 $10,600 - $16,299
10,000 Added 5.0%
210,000 $249,000
Q1 2024

May 14, 2024

BUY
$0.51 - $1.55 $17,850 - $54,250
35,000 Added 21.21%
200,000 $202,000
Q4 2023

Feb 12, 2024

BUY
$0.88 - $1.57 $26,400 - $47,100
30,000 Added 22.22%
165,000 $174,000
Q2 2023

Aug 15, 2023

BUY
$1.35 - $1.8 $6,750 - $9,000
5,000 Added 3.85%
135,000 $211,000
Q1 2023

May 15, 2023

BUY
$1.18 - $3.86 $20,060 - $65,620
17,000 Added 15.04%
130,000 $185,000
Q4 2022

Feb 14, 2023

BUY
$1.8 - $5.41 $5,400 - $16,230
3,000 Added 2.73%
113,000 $266,000
Q2 2022

Aug 15, 2022

BUY
$2.14 - $4.15 $12,840 - $24,900
6,000 Added 5.77%
110,000 $245,000
Q1 2022

May 13, 2022

BUY
$4.73 - $7.18 $9,460 - $14,360
2,000 Added 1.96%
104,000 $695,000
Q4 2021

Feb 11, 2022

BUY
$5.36 - $9.53 $10,720 - $19,060
2,000 Added 2.0%
102,000 $564,000
Q3 2021

Nov 12, 2021

BUY
$8.21 - $10.53 $46,797 - $60,020
5,700 Added 6.04%
100,000 $916,000
Q4 2020

Feb 09, 2021

BUY
$2.45 - $17.66 $83,300 - $600,440
34,000 Added 56.38%
94,300 $548,000
Q3 2020

Nov 13, 2020

BUY
$1.88 - $3.58 $113,364 - $215,874
60,300 New
60,300 $160,000

Others Institutions Holding SLS

About SELLAS Life Sciences Group, Inc.


  • Ticker SLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,551,900
  • Market Cap $24.3M
  • Description
  • SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...
More about SLS
Track This Portfolio

Track Equitable Holdings, Inc. Portfolio

Follow Equitable Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Equitable Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Equitable Holdings, Inc. with notifications on news.